CA2261343A1 - Formule de vaccin polynucleotidique aviaire - Google Patents
Formule de vaccin polynucleotidique aviaire Download PDFInfo
- Publication number
- CA2261343A1 CA2261343A1 CA002261343A CA2261343A CA2261343A1 CA 2261343 A1 CA2261343 A1 CA 2261343A1 CA 002261343 A CA002261343 A CA 002261343A CA 2261343 A CA2261343 A CA 2261343A CA 2261343 A1 CA2261343 A1 CA 2261343A1
- Authority
- CA
- Canada
- Prior art keywords
- vaccine
- virus
- seq
- plasmid
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000271566 Aves Species 0.000 title claims abstract description 33
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 title claims description 10
- 239000013612 plasmid Substances 0.000 claims abstract description 113
- 229960005486 vaccine Drugs 0.000 claims abstract description 74
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 71
- 241000700605 Viruses Species 0.000 claims abstract description 53
- 241000711450 Infectious bronchitis virus Species 0.000 claims abstract description 24
- 241000711404 Avian avulavirus 1 Species 0.000 claims abstract description 21
- 208000015181 infectious disease Diseases 0.000 claims abstract description 19
- 230000002458 infectious effect Effects 0.000 claims abstract description 16
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 claims abstract description 11
- 208000007502 anemia Diseases 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 244000052769 pathogen Species 0.000 claims abstract description 8
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 8
- 208000006758 Marek Disease Diseases 0.000 claims abstract description 4
- 238000001727 in vivo Methods 0.000 claims abstract description 4
- 238000002255 vaccination Methods 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- 206010035148 Plague Diseases 0.000 claims description 10
- 241000607479 Yersinia pestis Species 0.000 claims description 10
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 241000711902 Pneumovirus Species 0.000 claims description 6
- 206010044302 Tracheitis Diseases 0.000 claims description 6
- 201000002491 encephalomyelitis Diseases 0.000 claims description 6
- 201000009837 laryngotracheitis Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 101150029683 gB gene Proteins 0.000 claims description 4
- 101150010882 S gene Proteins 0.000 claims description 3
- 229940031551 inactivated vaccine Drugs 0.000 claims description 3
- 208000010359 Newcastle Disease Diseases 0.000 claims description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 2
- 108700004025 env Genes Proteins 0.000 claims description 2
- 101150030339 env gene Proteins 0.000 claims description 2
- 229940124551 recombinant vaccine Drugs 0.000 claims description 2
- 229940031626 subunit vaccine Drugs 0.000 claims 3
- 241000712469 Fowl plague virus Species 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 101150039660 HA gene Proteins 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 abstract description 4
- 102000040430 polynucleotide Human genes 0.000 abstract description 4
- 239000002157 polynucleotide Substances 0.000 abstract description 4
- 239000012634 fragment Substances 0.000 description 60
- 238000000034 method Methods 0.000 description 50
- 108020004414 DNA Proteins 0.000 description 47
- 230000000692 anti-sense effect Effects 0.000 description 44
- 239000002773 nucleotide Substances 0.000 description 44
- 125000003729 nucleotide group Chemical group 0.000 description 44
- 238000003757 reverse transcription PCR Methods 0.000 description 27
- 108091034117 Oligonucleotide Proteins 0.000 description 26
- 239000000047 product Substances 0.000 description 25
- 238000010276 construction Methods 0.000 description 21
- 238000000746 purification Methods 0.000 description 20
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 16
- 241000287828 Gallus gallus Species 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 108090000288 Glycoproteins Proteins 0.000 description 14
- 102000003886 Glycoproteins Human genes 0.000 description 14
- 235000013330 chicken meat Nutrition 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 9
- 241001223089 Tremovirus A Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 241000712461 unidentified influenza virus Species 0.000 description 6
- 101710081079 Minor spike protein H Proteins 0.000 description 5
- 241000702626 Infectious bursal disease virus Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 101500001532 Avian infectious bursal disease virus Capsid protein VP2 Proteins 0.000 description 3
- 241000711955 Turkey rhinotracheitis virus Species 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000001562 sternum Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000713826 Avian leukosis virus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- 101710128560 Initiator protein NS1 Proteins 0.000 description 2
- 101710144127 Non-structural protein 1 Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102100021696 Syncytin-1 Human genes 0.000 description 2
- 101150024766 VP1 gene Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 101150036031 gD gene Proteins 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 229940031346 monovalent vaccine Drugs 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229940031348 multivalent vaccine Drugs 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 101710197658 Capsid protein VP1 Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 101150023426 Ccin gene Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101150034814 F gene Proteins 0.000 description 1
- 101150080073 G1 gene Proteins 0.000 description 1
- 101150008820 HN gene Proteins 0.000 description 1
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 1
- 101000581803 Homo sapiens Lithostathine-1-beta Proteins 0.000 description 1
- 102100027338 Lithostathine-1-beta Human genes 0.000 description 1
- 101150098863 N1 gene Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 101150102573 PCR1 gene Proteins 0.000 description 1
- 101100476979 Rhodobacter capsulatus sdsA gene Proteins 0.000 description 1
- 101150027674 S1 gene Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000012768 mass vaccination Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/255—Marek's disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/22011—Dicistroviridae
- C12N2770/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FRFA9609339 | 1996-07-19 | ||
| FR9609339A FR2751225B1 (fr) | 1996-07-19 | 1996-07-19 | Formule de vaccin polynucleotidique aviaire |
| PCT/FR1997/001326 WO1998003659A1 (fr) | 1996-07-19 | 1997-07-16 | Formule de vaccin polynucleotidique aviaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2261343A1 true CA2261343A1 (fr) | 1998-01-29 |
Family
ID=9494451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002261343A Abandoned CA2261343A1 (fr) | 1996-07-19 | 1997-07-16 | Formule de vaccin polynucleotidique aviaire |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US6221362B1 (enExample) |
| EP (2) | EP1523992A1 (enExample) |
| JP (2) | JP2001503019A (enExample) |
| KR (1) | KR20000065258A (enExample) |
| CN (2) | CN1225685A (enExample) |
| AR (1) | AR013063A1 (enExample) |
| AU (1) | AU735184B2 (enExample) |
| BR (1) | BR9710495A (enExample) |
| CA (1) | CA2261343A1 (enExample) |
| CO (1) | CO4700304A1 (enExample) |
| DE (1) | DE69730839T2 (enExample) |
| ES (1) | ES2232876T3 (enExample) |
| FR (1) | FR2751225B1 (enExample) |
| HU (1) | HU224830B1 (enExample) |
| ID (1) | ID19475A (enExample) |
| MA (1) | MA24268A1 (enExample) |
| NZ (1) | NZ333779A (enExample) |
| TN (1) | TNSN97120A1 (enExample) |
| WO (1) | WO1998003659A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2751225B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique aviaire |
| ZA978434B (en) * | 1996-09-27 | 1998-03-26 | Akzo Nobel Nv | Inactivated vaccines. |
| US6468984B1 (en) * | 1999-06-08 | 2002-10-22 | Innovo Biotechnologies Ltd. | DNA vaccine for protecting an avian against infectious bursal disease virus |
| WO2000077218A1 (en) * | 1999-06-10 | 2000-12-21 | Agricultural Research Council | Vaccine for newcastle disease virus |
| AR031405A1 (es) * | 2000-11-21 | 2003-09-24 | Wyeth Corp | Metodos y vacunas para conferir proteccion in ovo contra la rinotraqueitis del pavo |
| FR2823222B1 (fr) | 2001-04-06 | 2004-02-06 | Merial Sas | Vaccin contre le virus de la fievre du nil |
| US7615209B2 (en) | 2001-09-12 | 2009-11-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions of NDV and methods of use thereof for treatment of cancer |
| IL145397A0 (en) * | 2001-09-12 | 2002-06-30 | Yissum Res Dev Co | Compositions and methods for treatment of cancer |
| US7037506B2 (en) * | 2002-03-08 | 2006-05-02 | Schweltzer Chemical Corporation Ltd. | Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry |
| US7029681B2 (en) * | 2002-03-08 | 2006-04-18 | Schweitzer Chemical Corporation | Multiple and multivalent DNA vaccines in ovo |
| EP1494708A1 (en) * | 2002-04-12 | 2005-01-12 | Capua, Ilaria | Purified subfragment codifying for neuroaminidase, recombinant neuroaminidase and its use in zooprophylaxis |
| US7524651B2 (en) | 2002-10-15 | 2009-04-28 | Wyeth | Assay methods for detection of a virus in an avian tissue sample |
| EP1606419A1 (en) | 2003-03-18 | 2005-12-21 | Quantum Genetics Ireland Limited | Systems and methods for improving protein and milk production of dairy herds |
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| US20050214316A1 (en) | 2003-11-13 | 2005-09-29 | Brown Thomas P | Methods of characterizing infectious bursal disease virus |
| MXPA06009452A (es) | 2004-02-19 | 2007-03-15 | Univ Alberta | Polimorfismos del promotor de leptin y sus usos. |
| DE602006013117D1 (de) | 2005-04-25 | 2010-05-06 | Merial Ltd | Nipah-virus-impfstoffe |
| US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
| DE102005040812A1 (de) * | 2005-08-27 | 2007-03-15 | Few Fahrzeugelektrikwerk Gmbh & Co. Kg | Elektrischer Anschluss sowie Verfahren zu dessen Verbindung mit der Scheibe eines Kraftfahrzeugs |
| US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| WO2007056614A1 (en) | 2005-11-14 | 2007-05-18 | Merial Limited | Gene therapy for renal failure |
| US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
| US20080274137A1 (en) * | 2007-05-02 | 2008-11-06 | Jean Christophe Francis Audonnet | DNA plasmids having improved expression and stability |
| CA2684923C (en) | 2007-05-02 | 2015-01-06 | Merial Limited | Dna plasmids having improved expression and stability |
| TW201004864A (en) * | 2008-06-03 | 2010-02-01 | Asahi Glass Co Ltd | Method for producing core-shell particle, core-shell particle, method for producing hollow particle, paint composition and article |
| MY159543A (en) | 2008-11-28 | 2017-01-13 | Merial Inc | Recombinant avian influenza vaccine and uses thereof |
| JP5797636B2 (ja) | 2009-04-03 | 2015-10-21 | メリアル リミテッド | ニューカッスル病ウイルスをベクターとするトリワクチン |
| MX351643B (es) | 2009-12-28 | 2017-10-23 | Merial Ltd | Antigeno ndv recombinante y usos del mismo. |
| US20130197612A1 (en) | 2010-02-26 | 2013-08-01 | Jack W. Lasersohn | Electromagnetic Radiation Therapy |
| NZ702145A (en) | 2010-03-12 | 2016-03-31 | Merial Inc | Bluetongue virus recombinant vaccines and uses thereof |
| BR112013007486B1 (pt) | 2010-08-31 | 2020-01-28 | Merial Ltd | composição, vetor recombinante de ndv e uso da referida composição |
| WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
| AU2012240240A1 (en) | 2011-04-04 | 2013-05-09 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| EP2694678A2 (en) | 2011-04-04 | 2014-02-12 | Netherland Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment |
| US9216213B2 (en) | 2011-04-20 | 2015-12-22 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
| EP2701736A1 (en) | 2011-04-25 | 2014-03-05 | Advanced Bioscience Laboratories, Inc. | Truncated hiv envelope proteins (env), methods and compositions related thereto |
| ES2764079T3 (es) | 2011-05-27 | 2020-06-02 | Boehringer Ingelheim Animal Health Usa Inc | Vacunas genéticas contra el virus Hendra y el virus Nipah |
| WO2012166493A1 (en) | 2011-06-01 | 2012-12-06 | Merial Limited | Needle-free administration of prrsv vaccines |
| LT2741740T (lt) | 2011-08-12 | 2017-08-10 | Merial, Inc. | Biologinių produktų, ypatingai vakcinų, vakuuminis konservavimas |
| EP2785373B1 (en) * | 2011-11-30 | 2019-11-20 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof |
| WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
| WO2013123219A1 (en) | 2012-02-14 | 2013-08-22 | Merial Limited | Rotavirus subunit vaccines and methods of making and use thereof |
| AU2013221502C1 (en) | 2012-02-14 | 2018-03-01 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom |
| WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
| JP6347257B2 (ja) | 2012-06-13 | 2018-06-27 | メリアル インコーポレイテッド | 再集合体ｂｔｖおよびａｈｓｖワクチン |
| CN102719567A (zh) * | 2012-07-05 | 2012-10-10 | 广东温氏食品集团有限公司 | 禽传染性支气管炎病毒h120毒株的pcr检测引物及检测方法 |
| HK1216006A1 (zh) | 2013-03-12 | 2016-10-07 | Boehringer Ingelheim Animal Health USA Inc. | 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法 |
| WO2015179417A1 (en) | 2014-05-19 | 2015-11-26 | Merial, Inc. | Method and device for conditional in ovo injection |
| IL241841B (en) * | 2014-09-30 | 2019-09-26 | Univ Free State | Production of proteins for human and animal health using yarrowia lipolytica |
| WO2016073410A1 (en) | 2014-11-03 | 2016-05-12 | Merial, Inc. | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
| CN104881148B (zh) * | 2015-05-15 | 2017-12-15 | 苏州达方电子有限公司 | 键盘及其控制方法 |
| US9981033B2 (en) | 2015-06-23 | 2018-05-29 | Merial Inc. | PRRSV minor protein-containing recombinant viral vectors and methods of making and use thereof |
| CN108135997A (zh) | 2015-08-20 | 2018-06-08 | 梅里亚股份有限公司 | Fcv重组疫苗及其用途 |
| CA3000352A1 (en) | 2015-09-29 | 2017-04-06 | Merial, Inc. | Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof |
| CN108367067B (zh) | 2015-11-23 | 2022-05-03 | 勃林格殷格翰动物保健美国公司 | Fmdv和e2的融合蛋白质及其用途 |
| TWI760322B (zh) | 2016-01-29 | 2022-04-11 | 美商百靈佳殷格翰動物保健美國有限公司 | 重組腺病毒載體裝載之fmdv疫苗及其用途 |
| CN107099513B (zh) * | 2017-06-22 | 2020-07-14 | 北京邦卓生物科技有限公司 | 一种共表达ndv hn和ibdv vp2基因的hvt的构建及其应用 |
| CN111727053B (zh) * | 2018-01-26 | 2024-06-25 | 全国农业协同组合连合会 | 非人动物用抗原表面结合型脂质体疫苗 |
| CN110777122A (zh) * | 2019-10-21 | 2020-02-11 | 青岛易邦生物工程有限公司 | 一种表达ibdv的vp2蛋白的重组ⅰ型马立克氏病病毒 |
| CN115089700B (zh) * | 2022-05-25 | 2025-07-25 | 永州中古生物技术有限公司 | 一种抗β属冠状病毒的疫苗组合物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0474676A4 (en) * | 1989-05-30 | 1993-02-24 | The Commonwealth Scientific And Industrial Research Organization | Production of ibdv vp2 in highly immunogenic form |
| JPH06509235A (ja) * | 1991-07-26 | 1994-10-20 | ヴァイロジェネティクス コーポレイション | 伝染性ファブリキウス嚢病ウイルス組換えポックスウイルスワクチン |
| FR2697534A1 (fr) * | 1992-11-02 | 1994-05-06 | Rhone Merieux | Virus herpès de la dinde recombinant pour la réalisation de vaccin de la maladie de Gumboro, son procédé de préparation et vaccin obtenu. |
| IL108915A0 (en) * | 1993-03-18 | 1994-06-24 | Merck & Co Inc | Polynucleotide vaccine against influenza virus |
| NZ263772A (en) * | 1993-04-14 | 1996-12-20 | Webster Arthur Pty Ltd | Recombinant avian adenovirus with heterologous nucleotide sequence; use as vector; vaccine |
| ATE475668T1 (de) * | 1994-01-27 | 2010-08-15 | Univ Massachusetts Medical | Immunisierung durch impfung von dns transkriptionseinheit |
| JPH08116976A (ja) * | 1994-10-20 | 1996-05-14 | Chemo Sero Therapeut Res Inst | 免疫用核酸調製物およびこれを用いた免疫方法 |
| US5736524A (en) * | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| FR2728794B1 (fr) * | 1994-12-30 | 1997-03-21 | Rhone Merieux | Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro |
| WO1996021034A1 (fr) * | 1994-12-30 | 1996-07-11 | Rhone Merieux | Vaccin vivant recombinant aviaire |
| FR2751225B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique aviaire |
| US5916879A (en) | 1996-11-12 | 1999-06-29 | St. Jude Children's Research Hospital | DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof |
| US6468984B1 (en) * | 1999-06-08 | 2002-10-22 | Innovo Biotechnologies Ltd. | DNA vaccine for protecting an avian against infectious bursal disease virus |
-
1996
- 1996-07-19 FR FR9609339A patent/FR2751225B1/fr not_active Expired - Lifetime
-
1997
- 1997-07-11 AR ARP970103112A patent/AR013063A1/es unknown
- 1997-07-15 TN TNTNSN97120A patent/TNSN97120A1/fr unknown
- 1997-07-16 CN CN97196561A patent/CN1225685A/zh active Pending
- 1997-07-16 NZ NZ333779A patent/NZ333779A/xx unknown
- 1997-07-16 DE DE69730839T patent/DE69730839T2/de not_active Expired - Lifetime
- 1997-07-16 ID IDP972482A patent/ID19475A/id unknown
- 1997-07-16 MA MA24715A patent/MA24268A1/fr unknown
- 1997-07-16 BR BR9710495A patent/BR9710495A/pt not_active Application Discontinuation
- 1997-07-16 WO PCT/FR1997/001326 patent/WO1998003659A1/fr not_active Ceased
- 1997-07-16 EP EP04021994A patent/EP1523992A1/fr not_active Withdrawn
- 1997-07-16 AU AU37736/97A patent/AU735184B2/en not_active Expired
- 1997-07-16 JP JP10506638A patent/JP2001503019A/ja active Pending
- 1997-07-16 EP EP97934579A patent/EP0914442B1/fr not_active Expired - Lifetime
- 1997-07-16 CN CNA2005100669793A patent/CN1701788A/zh active Pending
- 1997-07-16 KR KR1019980710910A patent/KR20000065258A/ko not_active Ceased
- 1997-07-16 ES ES97934579T patent/ES2232876T3/es not_active Expired - Lifetime
- 1997-07-16 CA CA002261343A patent/CA2261343A1/fr not_active Abandoned
- 1997-07-16 HU HU9902790A patent/HU224830B1/hu unknown
- 1997-07-18 CO CO97040980A patent/CO4700304A1/es unknown
-
1999
- 1999-01-15 US US09/232,479 patent/US6221362B1/en not_active Expired - Lifetime
-
2001
- 2001-02-16 US US09/784,990 patent/US6464984B2/en not_active Expired - Lifetime
-
2002
- 2002-08-28 US US10/229,412 patent/US20030124145A1/en not_active Abandoned
-
2008
- 2008-10-31 JP JP2008282541A patent/JP2009149608A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HU224830B1 (en) | 2006-02-28 |
| EP1523992A1 (fr) | 2005-04-20 |
| FR2751225A1 (fr) | 1998-01-23 |
| FR2751225B1 (fr) | 1998-11-27 |
| KR20000065258A (ko) | 2000-11-06 |
| ES2232876T3 (es) | 2005-06-01 |
| CN1225685A (zh) | 1999-08-11 |
| US6464984B2 (en) | 2002-10-15 |
| EP0914442A1 (fr) | 1999-05-12 |
| CO4700304A1 (es) | 1998-12-29 |
| JP2001503019A (ja) | 2001-03-06 |
| HUP9902790A2 (hu) | 1999-12-28 |
| ID19475A (id) | 1998-07-16 |
| WO1998003659A1 (fr) | 1998-01-29 |
| DE69730839D1 (de) | 2004-10-28 |
| JP2009149608A (ja) | 2009-07-09 |
| NZ333779A (en) | 2000-07-28 |
| US6221362B1 (en) | 2001-04-24 |
| TNSN97120A1 (fr) | 2005-03-15 |
| BR9710495A (pt) | 1999-08-17 |
| AR013063A1 (es) | 2000-12-13 |
| HUP9902790A3 (en) | 2000-03-28 |
| MA24268A1 (fr) | 1998-04-01 |
| US20030124145A1 (en) | 2003-07-03 |
| AU3773697A (en) | 1998-02-10 |
| US20020037292A1 (en) | 2002-03-28 |
| AU735184B2 (en) | 2001-07-05 |
| DE69730839T2 (de) | 2005-09-29 |
| EP0914442B1 (fr) | 2004-09-22 |
| CN1701788A (zh) | 2005-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0914442B1 (fr) | Formule de vaccin polynucleotidique aviaire | |
| EP0934416B1 (fr) | Formule de vaccin polynucleotidique felin | |
| EP0936922B1 (fr) | Formule de vaccin polynucleotidique contre les pathologies du cheval | |
| EP0954332B2 (fr) | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives | |
| EP0912194B1 (fr) | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins | |
| WO1998003660A9 (fr) | Formule de vaccin polynucleotidique felin | |
| EP0912743B1 (fr) | Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs | |
| EP0968297B1 (fr) | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire | |
| EP1185662B1 (fr) | Vaccins adn pour les chiens | |
| EP1066055A1 (fr) | Vaccins adn adjuves | |
| EP1490105B1 (en) | Multiple and multivalent dna vaccines in ovo | |
| AU2004210602B2 (en) | Avian polynucleotide vaccine formula | |
| AU777623B2 (en) | Avian polynucleotide vaccine formula | |
| AU2007202367A1 (en) | Avian polynucleotide vaccine formula |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |